Table 1.

Characteristics of the representative broadly neutralizing antibodies (bNAbs) summarized in this review.

Target Sites (See Figure 1)	bNAb	PDB Accession No. for Crystal Structure	Potency (Geometric Mean/Median IC50, μg/mL)	Breadth (% of n Pseudoviruses, IC50 < 50 μg/mL)	Research & Development Stage	References
CD4-binding	VRC01	3NGB	0.33/0.37	91% of 190	Phase I	[20,24]
site	3BNC117	4JPV	0.09/0.07	84% of 180	Phase II	[23]
V1/V2	PGDM1400	4RQQ	- */0.003	83% of 106	Preclinical	[27]
V3/Asn332	PGT121	4FQ1	0.05/0.022	64% of 177	Preclinical	[28,29]
glycan patch	10-1074	4FQ2	- **	57% of 119	Phase I	[28]
gp120/	PGT151	4NUG	- */0.008	66% of 117	Preclinical	[30,31]
gp41-	35O22	4TOY	0.056/0.033	62% of 181	Preclinical	[32]
interface	8ANC195	4P9M	- */0.85	57% of 118	Preclinical	[33,34]
MPER	10E8	4G6F	0.22/0.35	98% of 180	Preclinical	[35,36]

* The geometric mean IC₅₀ is not available; ** The geometric mean and median IC₅₀ are not available.